InflaRx IFRX
NASDAQ IFRX
$2.10 +0.08 (+3.96%)
At close: Aug 21, 2026 · 4:00 PM EDT

InflaRx (IFRX) Net Income towards Common Stockholders (2016 - 2026)

InflaRx (IFRX) posted Net Income towards Common Stockholders of -$6.5 million for Q1 2026, down 115.74% sequentially from $41.6 million in Q4 2025, and up 25.13% YoY from -$5.2 million in Q1 2025.

InflaRx (IFRX) Net Income towards Common Stockholders (2016 - 2026) Analysis & Trends

InflaRx has reported Net Income towards Common Stockholders for 11 years, with the latest figure at -$6.5 million in Q1 2026.

  • Quarterly Net Income towards Common Stockholders rose 25.13% year-over-year to -$6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (up 8.45% YoY) and the FY2025 annual result came in at -$51.9 million, down 4.05% from the prior year.
  • Net Income towards Common Stockholders declined to -$6.5 million in Q1 2026 per IFRX's latest filing, from $41.6 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $46.9 million in Q4 2024 and troughed at -$11896.7 billion in Q1 2023.
  • A 5-year average of -$699.8 billion and a median of -$8.9 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders slumped 83515793.71% in 2023, then soared 455.21% in 2024.
  • Over 5 years, Net Income towards Common Stockholders stood at $23.2 million in 2022, then plunged by 156.83% to -$13.2 million in 2023, then jumped by 455.21% to $46.9 million in 2024, then retreated by 11.25% to $41.6 million in 2025, then sank by 115.74% to -$6.5 million in 2026.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$6.5 million, $41.6 million, and -$14.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -782.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 237.01 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 164.49 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -174.37 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -13.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 81.49 Mn
10 InflaRx 140.30 Mn -43.96 Mn 2.74 Bn -7.28 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -6.55 Mn
Dec 31, 2025 41.61 Mn
Sep 30, 2025 -14.33 Mn
Jun 30, 2025 -16.32 Mn
Mar 31, 2025 -8.75 Mn
Dec 31, 2024 46.88 Mn
Sep 30, 2024 -19.16 Mn
Jun 30, 2024 -14.91 Mn
Mar 31, 2024 -10.49 Mn
Dec 31, 2023 -13.20 Mn
Sep 30, 2023 -8.11 Mn
Jun 30, 2023 -8.93 Mn
Mar 31, 2023 -11,896.74 Bn
Dec 31, 2022 23.22 Mn
Sep 30, 2022 -7.99 Mn
Jun 30, 2022 13.95 Mn
Mar 31, 2022 -14.24 Mn
Dec 31, 2021 -44,446.67 Bn
Sep 30, 2021 -14.22 Mn
Jun 30, 2021 17.80 Mn